OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019

(2020) Claus Garbe et al.   EUROPEAN JOURNAL OF CANCER

Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients

(2020) Zhen Lin et al.   Frontiers in Oncology

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience

(2019) Raphael J. Louie et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Oncolytic Viruses: Priming Time for Cancer Immunotherapy

(2019) Luke Russell et al.   BIODRUGS

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

(2019) Lu Si et al.   Translational Oncology

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

(2019) Robert H. I. Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

(2019) Robert H.I. Andtbacka et al.   EBioMedicine

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) O Michielin et al.   ANNALS OF ONCOLOGY

Burden of melanoma in China, 1990–2017: Findings from the 2017 global burden of disease study

(2019) Yan Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Enhancing oncolytic virotherapy: Observations from a Voronoi Cell-Based model

(2019) Adrianne L Jenner et al.   JOURNAL OF THEORETICAL BIOLOGY

Signaling and Function of Interleukin-2 in T Lymphocytes

(2018) Sarah H. Ross et al.   Annual Review of Immunology

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene laherparepvec: First in class oncolytic virotherapy

(2018) Robert M. Conry et al.   Human Vaccines & Immunotherapeutics

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

(2018) Omid Hamid et al.   BRITISH JOURNAL OF CANCER

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

(2018) Antoni Ribas et al.   CELL

Hippo Kinases Mst1 and Mst2 Sense and Amplify IL-2R-STAT5 Signaling in Regulatory T Cells to Establish Stable Regulatory Activity

(2018) Hao Shi et al.   IMMUNITY

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Intratumor and Intertumor Heterogeneity in Melanoma

(2017) Tomasz M. Grzywa et al.   Translational Oncology

The Natural History And Patterns Of Metastases From Mucosal Melanoma: An Analysis Of 706 Prospectively-Followed Patients

(2016) B Lian et al.   ANNALS OF ONCOLOGY

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy

(2016) Jun Ren et al.   OncoImmunology

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

BRAFmutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

(2013) D. Gonzalez et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

Evolution of oncolytic viruses: novel strategies for cancer treatment

(2013) Matthew J Atherton et al.   Immunotherapy

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

(2011) Lu Si et al.   EUROPEAN JOURNAL OF CANCER

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY